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Notifying Physicians and Patients About Medical 
Device Safety Issues: Thoughts from the FDA 
 
Mark Barnett* & Daniel Schultz** 
Over the past few months we have had the opportunity to 
interact with a number of groups who have a vital interest in 
device safety issues, and we are convinced that all of the key 
players—clinicians, patients, manufacturers, and regulators—
share the same overall goals: to assure that physicians have 
reliable and effective devices that will improve and even save 
patients’ lives, to be sure that adverse events, when they occur, 
are reported promptly and fully, and to provide physicians and 
patients with timely, usable information about these events so 
that they can take appropriate action.  Having said that, we 
also realize that each group brings to the table certain specific 
mandates and constraints that inform its viewpoint.  And so 
this colloquy serves an important function by providing an 
opportunity for the different views to be aired and discussed. 
We will begin by exploring the possible reasons for the 
recent upsurge of interest in patient and physician notification 
when medical devices malfunction.  We have recently 
experienced significant and widely publicized recalls of heart 
rhythm devices that have stimulated a great deal of public and 
professional interest.  But medical devices have been recalled 
in the past with far less discussion among manufacturers, 
physicians, and regulators.  What is different this time? 
Perhaps the most fundamental difference is that the FDA 
is now more frequently notifying the public, using press 
releases and website postings, in certain cases in which it is 
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vital that patients with the affected devices promptly seek 
medical advice.  Of course our traditional approach in getting 
the message out is to ask manufacturers, whom we regulate, to 
notify physicians, who in turn notify their patients.  That basic 
formula has not changed.  So why has FDA seen the need to 
supplement it with additional public notifications when serious 
adverse events occur? 
On the most basic level, the answer stems from a concern 
that patients may not always receive adequate notification 
from their physicians or that notification of physicians is not 
always adequate to reach all the patients that are affected.  
Despite good intentions and conscientious effort, some patients 
will inevitably fall through the cracks.  Recordkeeping, after 
all, is not always perfect, office staffs are busy, and patients 
move, change physicians, or change names.  Even those 
patients who are notified can misunderstand what they are 
told.   And so public notification by FDA adds an element of 
constructive redundancy to the system. 
There are also larger, societal trends that underpin and 
reinforce FDA’s increased involvement in patient notification.  
One is the increasing desire of patients to be active participants 
in their own health care and in making decisions that affect the 
treatment they receive.  Patients cannot carry out that role 
without receiving accurate, timely information about the drugs, 
vaccines, and devices that affect them. Increasingly, patients 
seek this information from the Internet, which includes dozens 
of health-related websites operated or supported by the 
government.  And so people today expect federal agencies like 
the FDA to provide them with the latest news—both good and 
bad—on medical products. 
Another impetus for FDA to take a more active role in 
notifying the public is a changing culture among federal 
agencies in which “transparency” is increasingly valued and 
encouraged.  To be “transparent” is to let people know about 
your agency’s decisions promptly and comprehensively, to 
explain why and how you took a particular action, and to 
provide this insight as early as possible.  But it is important to 
understand that while FDA is committed to transparency, it 
must also protect the confidentiality of trade secrets and 
confidential commercial information, as required by federal 
law.  Our goal is to provide the public with as much useful 
information as possible while at the same time meeting our 
legal obligations. 
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It is interesting to note that these two trends—patients 
seeking autonomy and federal agencies seeking to practice 
transparency—tend to reinforce one another.  The public 
desires information, and the government is motivated to 
provide it. 
But what does that do to the doctor-patient relationship?  
Everyone involved in this discussion will agree that a patient’s 
primary source of information about an implanted device 
should be the physician.  Only the physician can discuss a 
device problem with a patient in the context of that individual’s 
medical condition, history, lifestyle, and values, and only the 
physician can provide the personalized advice the patient needs 
to decide on a course of action. 
And so that presents a potential dilemma: how can we in 
the FDA continue to provide “constructive redundancy” by 
notifying the public about medical device problems, and yet at 
the same time avoid compromising the doctor-patient 
relationship? 
Part of the answer is to ensure that the content of FDA’s 
message to the public is consistent with what patients will hear 
from their doctors.  Although the FDA must speak with an 
independent voice, it is important to coordinate what we say, 
whenever possible, with manufacturers and clinicians, so that 
the patient receives one message that is accurate and 
consistent.  In crafting our messages for patients, our primary 
objective is to explain the situation and suggest a course of 
action—in most cases, to arrange to see their physicians—while 
at the same time not instilling needless anxiety. 
A second way to avoid compromising the doctor-patient 
relationship is to make sure that FDA’s messages are timed so 
as to avoid having patients learn about device problems from 
the news media before their physicians are informed.  Does this 
mean that we are promising to always inform clinicians before 
we inform the public?  No.  There will be instances when we 
will have to inform all groups simultaneously.  But we are 
mindful of the doctor-patient relationship, and we will make 
every effort to reinforce it. 
There are other, broader questions that also have a critical 
bearing on the issue of notifying physicians and patients about 
device malfunctions.  For example: 
? From a public health standpoint, how serious must 
a problem be in order to trigger a notification to 
physicians and patients?  Should a notification take 
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place even when a malfunction is not considered 
life-threatening? 
? How widespread must it be in order to trigger a 
notification?  Is just one report of a potentially life-
threatening malfunction sufficient?  How do we 
factor into this decision the worrisome question of 
underreporting? 
? How certain must we be about the nature of the 
problem, its causes, and its potential consequences 
before we decide to notify?  Early notification can 
potentially save lives, but notification before we 
have all the facts can invoke needless confusion and 
anxiety on the part of both patients and their 
doctors, and may actually compromise patient care. 
These are the kinds of questions all of us need to consider 
carefully as we move ahead to make decisions in this area. 
Of course even the best system for communicating 
information to physicians and patients cannot be effective 
without accurate, meaningful, up-to-date information to 
transmit.  And that brings us to the quality of the data that we 
receive from device manufacturers and our performance in 
acting on this information.  It has been all too apparent from 
recent news reports and editorials that in some cases 
manufacturers present adverse event data to us in a way that 
makes it difficult to identify and interpret the information, and 
that in some cases we are not as prompt as we should be in 
taking action. 
This is going to change.  We are committed to 
strengthening our postmarket surveillance system, better 
coordinating our postmarket and premarket activities, and 
facilitating more rapid response to critical device problems as 
they arise.  Here are just a few examples of this commitment. 
? We are more actively monitoring and enforcing the 
requirement that manufacturers of certain devices 
continue to conduct clinical studies after the 
product is approved. 
? We are developing a process through which more 
device manufacturers will be able to report adverse 
events electronically through our Medical Device 
Reporting (MDR) system, which should facilitate 
rapid reporting and more efficient interpretation of 
the reports on our end. 
? We are continuing to redirect our inspections of 
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device manufacturers in order to concentrate on 
those whose products pose the greatest risk, 
allowing us to target limited resources to areas of 
greatest public health concern. 
? We are developing guidance for companies that will 
more clearly define the kinds of manufacturing 
changes that will require notifying FDA, and what 
kinds of submissions will be needed. 
? We are developing a standard format for the annual 
reports that some manufacturers are required to 
submit to FDA in order to ensure that the 
information is complete and presented in a way 
that facilitates efficient FDA review. 
Like the other participants in the colloquy, we want 
patients to derive maximum benefit from medical devices at 
minimum risk.  To make that happen, we all must continue to 
develop a monitoring and reporting system that provides 
accurate information with rapid turnaround and gives 
physicians and patients useful information for making clinical 
decisions.  We look forward to working with the medical 
community, patient groups, and manufacturers to achieve that 
goal. 
 
 
 
 
